Amprenavir

  • #LGM Pharma is a Amprenavir CAS# 161814-49-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 161814-49-9
  • AHFC code: 08:18.08.08
  • Synonyms: AMP AMV VX-478
  • ATC Code: J05AE05 J05AE07
  • Chemical Formula: C13H17N5O8S2
  • Molecular Weight: 505.627
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00701 (APRD00605)
  • SMILES: CC(C)CN(C[C,,H](O)[C,H](CC1=CC=CC=C1)NC(=O)O[C,H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
  • InChl: YMARZQAQMVYCKC-OEMFJLHTSA-N
  • PubChem: 65016
  • IUPAC: (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate

Additional Details

Indication:
For the treatment of HIV-1 infection in combination with other antiretroviral agents.
Pharmacodynamics:
Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mode of Action:
Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Metabolism:
Hepatic. Amprenavir is metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. The 2 major metabolites result from oxidation of the tetrahydrofuran and aniline moieties. Glucuronide conjugates of oxidized metabolites have been identified as minor metabolites in urine and feces.
Toxicity:
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos